Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for MRT-8102 and MRT-6160, but lacks Phase 2 proof-of-concept results to fully derisk programs. Significant cash runway ($675m) and milestone-rich deals provide operational security while awaiting pivotal clinical readouts and potential Novartis milestones.
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.57 per share a year ago.
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17.64 per share on April 14, 2026. The sale represented 1.30% of their direct common stock holdings, reducing their directly held common shares from 613,471 to 605,471.
Monte Rosa Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 100 | $1,009.71 | $2,338 | $1,328.29 | 131.55% |
| BG Bart Gancher Intech Investment Management LLC | 18,878 | $164,366.26 | $439,668.62 | $275,302.36 | 167.49% |
 John H. Burbank III Passport Capital LLC | 4.35M | $25.87M | $101.21M | $75.34M | 291.23% |
 Joseph Castro Nuveen LLC | 120,872 | $1.9M | $2.82M | $921,044.69 | 48.6% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 392,227 | $6.23M | $9.19M | $2.96M | 47.6% |
Monte Rosa Therapeutics, Inc. (GLUE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Monte Rosa Therapeutics, Inc. ever had a stock split?
Monte Rosa Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Markus Warmuth CEO | NASDAQ (NGS) Exchange | 61225M102 CUSIP |
| US Country | 150 Employees | - Last Dividend | - Last Split | 24 Jun 2021 IPO Date |
Overview
Monte Rosa Therapeutics, Inc. is a pioneering clinical-stage biotechnology firm specializing in the creation of innovative small molecule precision medicines. Leveraging the body's natural protein degradation mechanisms, the company focuses on developing treatments for a variety of diseases by targeting proteins that are therapeutically relevant. Founded in 2019 and based in Boston, Massachusetts, Monte Rosa Therapeutics is at the forefront of biotechnological innovation, seeking to offer novel therapeutic options for various conditions by manipulating protein levels within the body.
Products and Services
- MRT-2359
- MRT-6160
- MRT-8102
- CDK2
An orally bioavailable molecular glue degrader designed to target the translation termination factor protein GSPT1. This product is aimed at treating MYC-driven tumors, offering a new approach in the battle against cancer by targeting the protein's influence on tumor growth and survival.
Developed for the treatment of systemic and central nervous system autoimmune diseases, MRT-6160 represents a significant advancement in the field of autoimmunity. Through its innovative mechanism, it targets specific pathways involved in autoimmune responses, offering potential relief for sufferers of these debilitating conditions.
Targeting IL-1/NLRP3 driven inflammatory diseases, MRT-8102 is a testament to Monte Rosa Therapeutics' commitment to combating inflammation through cutting-edge science. By focusing on the IL-1 and NLRP3 pathways, this product aims to provide effective treatment options for inflammatory diseases, highlighting the versatility of protein degradation technologies.
Specially developed to treat ovarian, uterine, and breast cancers, the CDK2 product line underscores the company's dedication to female health. Targeting the cyclin-dependent kinase 2 (CDK2) enzyme, which is often implicated in the proliferation of cancer cells, this treatment option holds the promise for significant advancements in the therapy of these prevalent cancers.
